Table 3.
MetS status | Frequency of MV‐PA | Number of People | Number of Death | Follow‐Up (Person‐Years) | Incidence Rate (/1000 Person‐Years) | Unadjusted Model | Multivariable Model | ||
---|---|---|---|---|---|---|---|---|---|
IRR (95% CI) | P Value | Adjusted IRR (95% CI) | P Value | ||||||
MetS‐free | 0 d/wk | 1 840 026 | 15 621 | 8 012 877 | 1.95 | Reference | Reference | ||
1–2 d/wk | 1 531 152 | 6733 | 6 896 304 | 0.98 | 0.50 (0.49–0.52) | <0.001 | 0.79 (0.77–0.82) | <0.001 | |
3–4 d/wk | 756 270 | 4145 | 3 377 828 | 1.23 | 0.63 (0.61–0.65) | <0.001 | 0.77 (0.74–0.80) | <0.001 | |
≥5 d/wk | 420 090 | 3559 | 1 832 813 | 1.94 | 1.00 (0.96–1.03) | 0.832 | 0.82 (0.79–0.85) | <0.001 | |
MetS‐recovery | 0 d/wk | 145 047 | 2376 | 616 827 | 3.85 | 1.98 (1.89–2.06) | <0.001 | 1.24 (1.19–1.29) | <0.001 |
1–2 d/wk | 104 911 | 760 | 470 783 | 1.61 | 0.83 (0.77–0.89) | <0.001 | 0.89 (0.82–0.95) | 0.001 | |
3–4 d/wk | 59 716 | 526 | 264 399 | 1.99 | 1.02 (0.94–1.11) | 0.647 | 0.88 (0.80–0.96) | 0.003 | |
≥5 d/wk | 38 639 | 489 | 165 185 | 2.96 | 1.52 (1.39–1.66) | <0.001 | 0.90 (0.82–0.99) | 0.025 | |
MetS‐developed | 0 d/wk | 156 540 | 2467 | 642 750 | 3.84 | 1.97 (1.89–2.05) | <0.001 | 1.10 (1.06–1.15) | <0.001 |
1–2 d/wk | 101 511 | 933 | 440 524 | 2.12 | 1.09 (1.02–1.16) | 0.014 | 1.03 (0.97–1.10) | 0.342 | |
3–4 d/wk | 54 830 | 550 | 233 594 | 2.35 | 1.21 (1.11–1.31) | <0.001 | 0.85 (0.78–0.92) | <0.001 | |
≥5 d/wk | 35 282 | 472 | 145 281 | 3.25 | 1.67 (1.52–1.83) | <0.001 | 0.79 (0.72–0.87) | <0.001 | |
MetS‐chronic | 0 d/wk | 406 137 | 7601 | 1 654 198 | 4.59 | 2.36 (2.29–2.42) | <0.001 | 1.09 (1.06–1.13) | <0.001 |
1–2 d/wk | 225 524 | 2368 | 977 978 | 2.42 | 1.24 (1.19–1.30) | <0.001 | 0.92 (0.88–0.96) | <0.001 | |
3–4 d/wk | 136 733 | 1663 | 579 996 | 2.87 | 1.470 (1.4–1.55) | <0.001 | 0.83 (0.79–0.87) | <0.001 | |
≥5 d/wk | 95 669 | 1577 | 390 821 | 4.04 | 2.07 (1.97–2.18) | <0.001 | 0.84 (0.80–0.89) | <0.001 |
Multivariable model was adjusted for baseline age, sex, estimated glomerular filtration rate (continuous, mL/min per 1.73 m2), alanine aminotransferase (continuous, IU/mL), aspartate aminotransferase (continuous, IU/mL), hemoglobin (continuous, g/dL), low‐income status (the lowest quartile in the nation), body mass index (continuous, kg/m2), Charlson Comorbidity Index score, and place of residence (urban or rural). IRR indicates incidence rate ratio; MACE, major adverse cardiovascular events; MetS, metabolic syndrome; and MV‐PA, moderate‐to‐vigorous physical activity.